9 December 2019 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today published advice accepting four new medicines.

Ruxolitinib (Jakavi) was accepted for the treatment of polycythaemia vera (PV). PV is a rare and incurable condition that causes too many red blood cells to be produced, reducing blood flow to the organs due to ‘thickening’ of the blood and occasionally the formation of blood clots.

Lanadelumab (Takhzyro) was accepted for the routine prevention of frequent severe attacks of hereditary angioedema.

Read SMC press release